

Amendments To The Claims:


DT01 Rec'd PCT/PTC 20 JAN 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

Claim 1 (Original): A method for the treatment or prophylaxis of a disease or condition, said disease or condition characterized by misregulation of a protein kinase, comprising administering of a compound of Formula (I):




(I)

including salts, solvates, and pharmaceutically acceptable derivatives thereof,

wherein A is H, alkyl, or aryl;

R¹ is D¹, D², D³, D⁴, or D⁵,

wherein D¹ is



and R³ and R⁴ are each independently H, alkyl, alkylsulfonyl, or -C(O)-(CH₂)_x-R⁵,


where R^5 is alkyl, acyl, alkoxy, $-(O)-(CH_2)_x-(O)-$ alkyl, or $-NR^6R^7$,

where R^6 and R^7 are each independently H or alkyl, or

R^6 and R^7 combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen,

or R^3 and R^4 combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, alkoxy, acyl, or halogen;

wherein D^2 is




and R^8 is alkyl, or $-NR^9R^{10}$,

where R^9 and R^{10} are each independently selected from H, alkyl, or $-(CH_2)_x-NR^6R^7$,

where R^6 and R^7 are each independently H or alkyl,

or R^6 and R^7 combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen;

wherein D³ is



and

the dashed line represents an optional double bond;

when R¹¹ is -(CH₂)_x, the optional dashed double bond does not exist, and R¹² is alkylsulfonyl or -NR¹³R¹⁴,


where R¹³ and R¹⁴ are each independently selected from H, alkyl, -(CH₂)_x-R¹⁷, where R¹⁷ is alkoxy or -NR¹⁵R¹⁶,

where R¹⁵ and R¹⁶ are each independently H or alkyl,

or R¹³ and R¹⁴ combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl or -(CH₂)_x-OH;

when R¹¹ is -(CH)-, the optional dashed double bond exists, and R¹² is -(CH)-C(O)-OH;

wherein D⁴ is



and R¹⁷ is hydroxy, alkoxy, or -NR¹⁸R¹⁹,

where R¹⁸ and R¹⁹ are each independently selected from H, alkyl, -(CH₂)_x-R²⁰,

where R²⁰ is alkylsulfonyl, hydroxy, aryl said aryl optionally substituted with hydroxy or alkoxy, heteroaryl, or -NR²¹R²²,

where R²¹ and R²² are each independently selected from H, acyl, alkyl,

or R²¹ and R²² combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted with alkyl or -(CH₂)_x-OH;

or R¹⁸ and R¹⁹ combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted with -(CH₂)_x-R²³,

where R²³ is alkoxy, hydroxy, -C(O)-R²⁴, where R²⁴ is a 5- or 6- membered ring optionally containing one or more heteroatoms and optionally containing one or more degrees of unsaturation, or -NR²⁵R²⁶, where R²⁵ and R²⁶ are each independently H or alkyl;

wherein D⁵ is

a 5- or 6- membered ring, optionally containing one or more heteroatoms, optionally containing one or more degrees of unsaturation, optionally fused with an additional 5- or 6- membered ring that optionally contains one or more heteroatoms and optionally contains one or more degrees of unsaturation,

wherein the ring or fused ring system may be optionally substituted one or more times with halogen, alkyl, haloalkyl, alkylsulfonyl, alkylthio, hydroxy, alkoxy, oxo, sulfonyl, sulfate ion, nitro, cyano, carboxy, alkoxycarbonyl, aryl where said aryl may be optionally substituted with sulfamoyl, heteroaryl where said heteroaryl may be optionally substituted with alkyl, or -NR²⁷R²⁸,

where R²⁷ and R²⁸ are each independently H, alkyl, acyl, alkoxy, alkoxycarbonyl, carboxy, or -(CH₂)_x-NR²⁹R³⁰, where R²⁹ and R³⁰ are each independently selected from H and alkyl,

or R²⁷ and R²⁸ combine to form a 5- or 6- membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen,

or -(O)_y-(CH₂)_x-R³¹, where R³¹ is hydroxy, alkoxy, haloalkyl, aryl optionally substituted with halogen, or -NR²⁷R²⁸, where R²⁷ and R²⁸ are as defined above;

provided that if D⁵ is phenyl, said phenyl must be substituted

wherein for each occurrence, x independently is 0, 1, 2, or 3; and

wherein for each occurrence, y independently is 0 or 1.

Claim 2 (Original): The method of claim 1 wherein R¹ is D⁵; and D⁵ is pyridyl substituted one or more times with alkoxy, halogen, -NR²⁷R²⁸, where R²⁷ is H or alkyl, and

R^{28} is H, alkyl, acyl, alkoxy carbonyl, or $-(CH_2)_x-NR^{29}R^{30}$,
where x is 2 and R^{29} and R^{30} are each alkyl, or
 $-(O)_y-(CH)_x-R^{31}$,
where y is 1, x is 2, and R^{31} is $-NR^{27}R^{28}$, where R^{27} and R^{28} are each alkyl.

Claim 3 (Original): The method of claim 1 wherein R^1 is D^5 ; and D^5 is quinolinyl.

Claim 4 (Original): The method of claim 1 wherein R^1 is D^5 ; and D^5 is piperadinylo optionally substituted with alkoxy carbonyl.

Claim 5 (Original): The method of claim 1 wherein R^1 is D^2 ; and R^8 is $-NR^9R^{10}$,
where R^9 is H, and
 R^{10} is H or $-(CH_2)_x-NR^6R^7$,
where x is 2 or 3, and
 R^6 and R^7 are each alkyl or
 R^6 and R^7 combine to form morpholinyl or pyrrolidinyl.

Claim 6 (Original): The method of claim 1 wherein R^1 is D^4 ; and R^{17} is hydroxy or $-NR^{18}R^{19}$,
where R^{18} is H or alkyl, and
 R^{19} is $-(CH_2)_x-R^{20}$,
where x is 2 or 3, and
 R^{20} is alkylsulfonyl, pyridyl, imidazolyl, or $-NR^{21}R^{22}$,
where R^{21} and R^{22} are each H or alkyl, or
 R^{21} and R^{22} combine to form piperidinyl, pyrrolidinyl,
morpholinyl, or piperazinyl, each optionally substituted with alkyl, or
 R^{18} and R^{19} combine to form piperizinyl optionally substituted with $-(CH_2)_x-R^{23}$,
where x is 2 and R^{23} is alkoxy or $-NR^{25}R^{26}$,

where R²⁵ and R²⁶ are each alkyl.

Claim 7 (Original): The method of claim 1 wherein R¹ is D⁵; and
D⁵ is phenyl substituted one or more times with alkoxy carbonyl, hydroxy,
halogen, alkoxy, carboxy, or -(O)_y-(CH₂)_x-R³¹,
where y is 0 or 1,
x is 1 or 2, and
R³¹ is hydroxy.

Claim 8 (Original): The method of claim 1 wherein the kinase is a
serine/threonine kinase.

Claim 9 (Original): The method of claim 1 wherein the kinase is GSK3.

Claim 10 (Original): The method of claim 1 wherein the kinase is a tyrosine
kinase.

Claim 11 (Original): The method of claim 1 wherein the kinase is TIE2.

Claim 12 (Original): The method of claim 1 wherein the disease or condition is
type 2 diabetes, hyperlipidemia, obesity, CNS disorders, neurotraumatic
injuries, immune potentiation, baldness or hair loss, atherosclerotic
cardiovascular disease, hypertension, polycystic ovary syndrome, ischemia,
immunodeficiency, or cancer.

Claim 13 (Original): The method of claim 1 wherein the disease or condition is
type 2 diabetes and the method further comprises administering at least one
additional anti-diabetic agent.

Claims 14-20 (Cancelled)